TY  - JOUR
AU  - Tap, William D
AU  - Wagner, Andrew J
AU  - Schöffski, Patrick
AU  - Martin-Broto, Javier
AU  - Krarup-Hansen, Anders
AU  - Ganjoo, Kristen N
AU  - Yen, Chueh-Chuan
AU  - Abdul Razak, Albiruni R
AU  - Spira, Alexander
AU  - Kawai, Akira
AU  - Le Cesne, Axel
AU  - Van Tine, Brian A
AU  - Naito, Yoichi
AU  - Park, Se Hoon
AU  - Fedenko, Alexander
AU  - Pápai, Zsuzsanna
AU  - Soldatenkova, Victoria
AU  - Shahir, Ashwin
AU  - Mo, Gary
AU  - Wright, Jennifer
AU  - Jones, Robin L
AU  - ANNOUNCE Investigators
PY  - 2020
DO  - 10.1001/jama.2020.1707
UR  - http://hdl.handle.net/10668/15335
T2  - JAMA
AB  - Patients with advanced soft tissue sarcoma (STS) have a median overall survival of less than 2 years. In a phase 2 study, an overall survival benefit in this population was observed with the addition of olaratumab to doxorubicin over doxorubicin...
LA  - en
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibiotics, Antineoplastic
KW  - Antibodies, Monoclonal
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Double-Blind Method
KW  - Doxorubicin
KW  - Drug Administration Schedule
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Placebos
KW  - Proportional Hazards Models
KW  - Sarcoma
KW  - Survival Analysis
KW  - Young Adult
TI  - Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial.
TY  - research article
VL  - 323
ER  -